Managing liquidity risk through cash-flow planning and available liquidity
First written in FY2019. 5 of 11 entries say "Worsened", first in FY2022. Latest entry: 2026-08-06.
Fuji Pharma moved to the "Worse" side of this theme in 2022, 2 years before the typical company in this theme (2024).
12 other companies' latest entry also says "Mitigated".
- FY2025-H1MitigatedAnnual report
「Cash and cash equivalents at the end of the current interim consolidated fiscal period were ¥6,695 million.」
Cash and cash equivalents increased from ¥4,585 million at the end of the previous consolidated fiscal year to ¥6,695 million, while cash flow from operating activities was also an inflow of ¥2,131 million, indicating an improvement from the decline in liquidity on hand through the previous fiscal year. - FY2024-Q2WorsenedAnnual report
「Cash and cash equivalents at the end of the second quarter of the current consolidated fiscal year were ¥1,375 million.」
Cash and cash equivalents decreased from ¥2,324 million at the end of the previous consolidated fiscal year to ¥1,375 million, while cash flow from operating activities was also an outflow of ¥445 million, indicating lower liquidity on hand. - FY2024-Q1WorsenedAnnual report
「Cash and deposits ¥2,324 million ¥2,161 million」
Cash and deposits decreased from ¥2,324 million at the end of the previous consolidated fiscal year to ¥2,161 million, indicating lower liquidity on hand. - FY2023-Q3WorsenedAnnual report
「Cash and deposits ¥3,546 million ¥3,975 million」
Cash and deposits increased by ¥429 million from the end of the previous consolidated fiscal year, but decreased from ¥5,282 million at the end of the previous quarter, indicating lower liquidity on hand compared with the most recent quarter. - FY2023-Q2MitigatedAnnual report
「Cash and cash equivalents at the end of the second quarter of the current consolidated fiscal year were ¥5,282 million.」
Cash and cash equivalents increased from ¥3,546 million at the end of the previous consolidated fiscal year to ¥5,282 million, while cash flow from operating activities was also an inflow of ¥1,516 million. This represents an improvement from the deterioration in liquidity reported through the previous quarter. - FY2023-Q1WorsenedAnnual report
「(Assets) Current assets increased by ¥2,182 million, mainly because increases in notes and accounts receivable outweighed the decrease in cash and deposits. Fixed assets increased by ¥2,977 million, mainly due to an increase in investment securities.」
Cash and deposits decreased by ¥475 million from ¥3,546 million at the end of the previous consolidated fiscal year to ¥3,071 million, indicating a deterioration in liquidity. - FY2022WorsenedAnnual report
「Cash and cash equivalents at the end of the current consolidated fiscal year decreased by ¥6,653 million from the end of the previous fiscal year to ¥3,546 million.」
Cash and cash equivalents decreased by ¥6,653 million from the end of the previous fiscal year to ¥3,546 million. Cash flow from operating activities was also an outflow of ¥658 million, indicating a change in liquidity. - FY2021RestatedAnnual report
「Current liabilities, including trade payables, are exposed to liquidity risk when settled. The company manages liquidity risk by preparing and updating a monthly cash-flow plan and maintaining liquidity on hand.」
The company continues to maintain its policy of managing liquidity risk associated with trade payables through monthly cash-flow planning and liquidity on hand. - FY2019First statedAnnual report
「Bills payable and accounts payable, which are trade payables, are due for payment within one year. These and other current liabilities are exposed to liquidity risk when settled. The company manages liquidity risk by preparing and updating a monthly cash-flow plan and maintaining liquidity on hand.」
The company has newly reported liquidity risk relating to trade payables due for settlement within one year, and its management through monthly updates to the cash-flow plan and maintenance of liquidity on hand.